Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
11. Januar 2022 07:00 ET
|
Amryt Pharma plc
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment...
Key Dates for AIM Delisting
06. Januar 2022 02:00 ET
|
Amryt Pharma plc
Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6, 2022, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the “Company”), a global, commercial-stage...
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
04. Januar 2022 07:00 ET
|
Amryt Pharma plc
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients DUBLIN, Ireland, and Boston MA, January 4,...
Total Voting Rights
04. Januar 2022 02:00 ET
|
Amryt Pharma plc
Total Voting Rights DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...
Total Voting Rights
01. Dezember 2021 02:00 ET
|
Amryt Pharma plc
Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...
Director/PDMR Shareholding
30. November 2021 02:00 ET
|
Amryt Pharma plc
Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the...
Amryt Provides Update on Regulatory Review Process for Oleogel-S10
23. November 2021 07:00 ET
|
Amryt Pharma plc
Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now expected in January 2022 DUBLIN, Ireland,...
Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
22. November 2021 02:00 ET
|
Amryt Pharma plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE...
Amryt Reports Strong Q3 2021 Results
03. November 2021 07:00 ET
|
Amryt Pharma plc
Amryt Reports Strong Q3 2021 Results 14.6% YoY revenue growth in Q3 to $56.5M 21.5% growth in metreleptin revenues YoY to $36.3M in Q3; 51.6% growth YoY excluding the impact of sporadic LATAM...
Total Voting Rights
01. November 2021 09:00 ET
|
Amryt Pharma plc
Total Voting Rights DUBLIN, Ireland, and Boston MA, November 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...